Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Colicin E4 has been iodinated with ['251]iodine. The relationship between the degree of iodination and the biological activity has been determined. In contrast to colicins E2, E3, Ia, Ib or cloacin, conventional saturation curves with sensitive cells are not obtained with colicin E4. A turnover ofcolicin on the receptors is evidenced. Analysis of the colicin molecules (M, 56000 2000) incubated in buffer with sensitive cells, on sodium dodecylsulfate/polyacrylamide gels shows that cleavage of the colicin molecules occurs to yield two fragments of 27000 M , and 26000 M, respectively. Strains selected for resistance to colicin E4 are defective in their ability to cleave this bacteriocin, whereas tolerant strains, which have an intact receptor but are not killed by colicin E4. cleave like sensitive cells. Colicin -receptors interaction, which results in cleavage, is much less sensitive to the degree of iodination than the biological activity. Kinetics of cleavage as well as the effect of various treatments of sensitive cells are described. Among the various parameters which alter the cleavage, the most interesting is the ionic strength effect. In the presence of 0.5",, or 1 0 o NaC1. colicin E4 cleavage practically is not evidenced. We suggest that the equilibrium constant of the colicin-receptor complex is very sensitive to ionic strength. The mechanism of colicin E4 cleavage with regard to the killing action is discussed.The early hypothesis presented by Fredericq in 1946 [ l ] which postulated that bacteria sensitive to a given colicin contain a specific receptor substance on their surface, which serves as the site of attachment for the bacteriocin, has been fully confirmed in recent years. There is a wide agreement that a first step in the killing of Escherichirr coli by colicins is the adsorption of colicin molecules to receptor sites on the bacterial surface. In the case of colicins E2, €3 [2], Ia and Ib [3,4] and of cloacin [5], binding of radioactive colicins to cells was measured directly. In the accompanying study [6] we described the purification and the molecular properties of colicin E4. This bacteriocin causes physiological effects similar to those caused by colicins E l , K , Ia, Ib and L-JF246. The aim of this work was to study the conditions and the effects of the interaction of colicin E4 with its receptor site. We present evidence which suggests that, in contrast to all colicins previously studied [7], colicin E4 undergoes a turnover on the receptor sites triggering a proteolytic activity cleaving the colicin molecules like a substrate and releasing two fragments devoid of h-rm,. Lactoperoxidase (EC 1 .1 1.1 .7).
Colicin E4 has been iodinated with ['251]iodine. The relationship between the degree of iodination and the biological activity has been determined. In contrast to colicins E2, E3, Ia, Ib or cloacin, conventional saturation curves with sensitive cells are not obtained with colicin E4. A turnover ofcolicin on the receptors is evidenced. Analysis of the colicin molecules (M, 56000 2000) incubated in buffer with sensitive cells, on sodium dodecylsulfate/polyacrylamide gels shows that cleavage of the colicin molecules occurs to yield two fragments of 27000 M , and 26000 M, respectively. Strains selected for resistance to colicin E4 are defective in their ability to cleave this bacteriocin, whereas tolerant strains, which have an intact receptor but are not killed by colicin E4. cleave like sensitive cells. Colicin -receptors interaction, which results in cleavage, is much less sensitive to the degree of iodination than the biological activity. Kinetics of cleavage as well as the effect of various treatments of sensitive cells are described. Among the various parameters which alter the cleavage, the most interesting is the ionic strength effect. In the presence of 0.5",, or 1 0 o NaC1. colicin E4 cleavage practically is not evidenced. We suggest that the equilibrium constant of the colicin-receptor complex is very sensitive to ionic strength. The mechanism of colicin E4 cleavage with regard to the killing action is discussed.The early hypothesis presented by Fredericq in 1946 [ l ] which postulated that bacteria sensitive to a given colicin contain a specific receptor substance on their surface, which serves as the site of attachment for the bacteriocin, has been fully confirmed in recent years. There is a wide agreement that a first step in the killing of Escherichirr coli by colicins is the adsorption of colicin molecules to receptor sites on the bacterial surface. In the case of colicins E2, €3 [2], Ia and Ib [3,4] and of cloacin [5], binding of radioactive colicins to cells was measured directly. In the accompanying study [6] we described the purification and the molecular properties of colicin E4. This bacteriocin causes physiological effects similar to those caused by colicins E l , K , Ia, Ib and L-JF246. The aim of this work was to study the conditions and the effects of the interaction of colicin E4 with its receptor site. We present evidence which suggests that, in contrast to all colicins previously studied [7], colicin E4 undergoes a turnover on the receptor sites triggering a proteolytic activity cleaving the colicin molecules like a substrate and releasing two fragments devoid of h-rm,. Lactoperoxidase (EC 1 .1 1.1 .7).
Extraction of the crude cell envelope fraction of cloacin DF13-susceptible Enterobacter cloacae strain 02 with Triton X-100 and ethylenediaminetetraacetate solubilized an outer membrane fraction which neutralized the lethal activity of cloacin DF13. A similar fraction could not be isolated from strains known to be lacking functional cloacin DF13 receptors. On this basis the isolated outer membrane fraction was assumed to contain the specific cloacin DF13 receptor. The receptor was purified to homogeneity by acetone precipitation and affinity chromatography, using cloacin DF13 as a ligand. The purified receptor was identified as a protein which consisted of a single polypeptide chain with an apparent molecular weight of 90,000 and a preponderance of acidic amino acids (pI = 5.0). The interaction of equimolar amounts of purified receptor and cloacin DF13 in vitro resulted in a complete, irreversible neutralization of the lethal activity of the bacteriocin. This interaction showed a temperature optimum at 430C but was only slightly affected by variation of the pH beween 5.0 and 8.5 or by increasing the ionic strength of the incubation buffer. The receptor had no neutralizing activity towards other bacteriocins, such as colicin El or colicin E3.Cloacin DF13 is a bacteriocin produced by bacteriocinogenic strains of Enterobacter cloacae(CloDF13) (16,47). It is characterized by its ability to kill cells of susceptible strains of Enterobacter and Klebsiella species (16). The bacteriocin is excreted as an equimolar complex of two CloDF13-determined gene products, designated cloacin and immunity protein (13). The cloacin inactivates bacterial ribosomes by endoribonucleolytic cleavage of 16S rRNA and induces a leakage of potassium ions from the susceptible cells (12,14,15). The immunity protein serves as an inhibitor of the endoribonucleolytic activity of the cloacin through a direct and specific stoichiometric interaction with the cloacin molecules (34).The initial event in the killing of susceptible bacteria by cloacin DF13 involves recognition of and binding to specific receptors localized on the surface of the cells (16,35). Recently, it has been reported that whole cells of cloacin DF13-susceptible E. cloacae strain 02 grown in brain heart infusion each adsorb about 425 molecules of cloacin DF13 (35). This adsorption has a temperature optimum between 35 and 400C, but it is not affected by variation in pH between 5.0 and 8.0 or by extracellular potassium chloride up to a concentration of 0.5 M. However, little is known about the nature of the interaction of this bacteriocin and its receptor or about the sequence of events that, after adsorption, leads to the biochemical effects observed.All receptors for bacteriocins affecting gramnegative bateria studied so far have been localized in the outer membrane fraction of the cell envelope (6,7,30,39,45,50). Furthermore, it has been shown that some of these receptors also serve as the attachment sites for certain bacteriophages and that they facilitate the passage of low-molec...
SUMMARY Colicins are proteins produced by and toxic for some strains of Escherichia coli. They are produced by strains of E. coli carrying a colicinogenic plasmid that bears the genetic determinants for colicin synthesis, immunity, and release. Insights gained into each fundamental aspect of their biology are presented: their synthesis, which is under SOS regulation; their release into the extracellular medium, which involves the colicin lysis protein; and their uptake mechanisms and modes of action. Colicins are organized into three domains, each one involved in a different step of the process of killing sensitive bacteria. The structures of some colicins are known at the atomic level and are discussed. Colicins exert their lethal action by first binding to specific receptors, which are outer membrane proteins used for the entry of specific nutrients. They are then translocated through the outer membrane and transit through the periplasm by either the Tol or the TonB system. The components of each system are known, and their implication in the functioning of the system is described. Colicins then reach their lethal target and act either by forming a voltage-dependent channel into the inner membrane or by using their endonuclease activity on DNA, rRNA, or tRNA. The mechanisms of inhibition by specific and cognate immunity proteins are presented. Finally, the use of colicins as laboratory or biotechnological tools and their mode of evolution are discussed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.